Written by According to Fortune Business Insights, the global cardiac resynchronization therapy market size was valued at USD 6.96 billion in 2025 and is projected to grow from USD 7.26 billion in 2026 to USD 9.72 billion by 2034, exhibiting a CAGR of 3.7% during the forecast period from 2026 to 2034. North America dominated the global market with a 44.25% share in 2025, supported by advanced cardiac care infrastructure and the high adoption of device-based therapies.
Market Overview
The growing burden of heart failure represents one of the primary factors supporting demand for cardiac resynchronization therapy. According to the source, HF Stats 2025 estimates that approximately 6.7 million Americans over the age of 20 live with heart failure, with prevalence expected to increase in the coming years.
CRT is increasingly incorporated into multidisciplinary heart failure pathways involving imaging, guideline-directed medical therapy, and electrophysiology assessment. Greater awareness of treatment eligibility and improvements in referral pathways are helping healthcare providers identify patients who may benefit from device therapy.
For detailed market insights: https://www.fortunebusinessinsights.com/cardiac-resynchronization-therapy-market-113171
Market Trends
Device Connectivity and Remote Patient Monitoring
One of the most important trends in the cardiac resynchronization therapy market is the growing importance of connectivity and remote follow-up. Healthcare providers are seeking systems that can reduce the burden on clinics while maintaining effective patient monitoring.
Remote monitoring and app-based connectivity can streamline alerts, reduce routine visits, and help healthcare professionals identify potential patient deterioration earlier. This is particularly relevant as heart failure patient volumes increase and electrophysiology workforces remain constrained.
Greater Interest in Physiologic Pacing
The market is also witnessing growing interest in approaches designed to support more physiologic activation. Conduction-system pacing concepts and devices compatible with newer implantation techniques may increase treatment feasibility for patients who present complex clinical or anatomical challenges.
Guidelines also continue to influence the market by promoting systematic patient selection and follow-up and by positioning device therapy alongside modern pharmacological treatment.
Market Drivers
Growing Heart Failure Patient Pool
The increasing prevalence of heart failure is a major driver of the cardiac resynchronization therapy market. As the number of patients requiring advanced heart failure management increases, demand for device-based treatment is expected to rise.
Expanding Guideline-Based Eligibility
Clearer, guideline-based decision-making is encouraging eligible patients to undergo evaluation for CRT instead of remaining under prolonged observation. Multidisciplinary heart failure programs increasingly coordinate imaging, medical therapy optimization, and electrophysiology assessments, helping reduce the possibility of eligible patients being overlooked.
Professional guidelines, including European heart failure recommendations, continue to provide structured approaches to diagnosis, pharmacotherapy, and device therapy. This standardization is supporting the adoption of CRT across healthcare settings.
However, high procedural complexity, specialized equipment requirements, variable patient response, and the total cost of therapy can restrain market growth. CRT implantation requires specialized operators, careful lead placement, post-implant optimization, and continued programming and follow-up.
Market Segmentation
By Product
Based on product, the market is divided into CRT-Defibrillator and CRT-Pacemakers.
The CRT-Defibrillator segment is expected to hold the larger market share. Many CRT candidates also face an elevated risk of serious ventricular arrhythmias, making combined resynchronization and defibrillation attractive for eligible patients. This is particularly relevant among patients with ischemic cardiomyopathy and higher-risk profiles.
The CRT-Pacemakers segment is projected to grow at a CAGR of 5.7% during the forecast period.
By Application
The market is categorized into heart failure management, arrhythmia management, and others.
Heart failure management dominates the application segment because CRT is primarily used to improve mechanical efficiency in patients with symptomatic heart failure and ventricular dyssynchrony. The segment is projected to hold an 80.0% share in 2026.
The arrhythmia management segment is estimated to grow at a CAGR of 1.7% during the forecast period.
By End-user
Based on end-user, the market is segmented into hospitals and ASCs, specialty clinics, and others.
Hospitals and ASCs account for the largest share because CRT implantation requires a sterile procedural environment, imaging capabilities, device-testing facilities, emergency cardiac support, and specialized electrophysiology teams. The segment is set to hold a 90.6% share in 2026.
Meanwhile, the specialty clinics segment is projected to grow at a CAGR of 6.2% during the forecast period.
Key Players
The major companies operating in the cardiac resynchronization therapy market include Medtronic plc, Abbott, Boston Scientific, and BIOTRONIK SE & Co. KG. These companies maintain strong positions through investments in product development, new device introductions, alliances, and partnerships.
Other companies highlighted in the source include MicroPort Scientific, EBR Systems, MEDICO S.p.A., and OSYPKA.
Regional Analysis
North America
North America held the largest position in the global cardiac resynchronization therapy market, accounting for 44.25% of the market in 2025. The regional market was valued at USD 3.08 billion in 2025, supported by advanced cardiac care infrastructure, strong referral networks, and the adoption of advanced device technologies.
The U.S. market is projected to reach USD 2.92 billion in 2026, representing 40.2% of global revenue.
Europe
Europe is projected to reach USD 1.85 billion in 2026. Growth is supported by the increasing burden of cardiovascular disease, established healthcare infrastructure, and guideline-based approaches to heart failure management.
Asia Pacific
Asia Pacific is expected to reach USD 0.53 billion in 2026. Improving healthcare access and opportunities to expand implant capacity and specialist training are supporting regional growth.
Other Regions
Latin America and the Middle East & Africa also represent opportunities for market expansion. The source highlights the potential for greater CRT penetration in regions where eligible patients remain undertreated because of infrastructure, training, and access limitations.
Competitive Landscape
Competition in the cardiac resynchronization therapy market is driven by product innovation, technological development, strategic partnerships, and improvements in patient monitoring. Leading companies are investing in devices that provide improved longevity, connectivity, and workflow efficiency.
Recent industry developments demonstrate the focus on new approaches. In April 2025, EBR Systems received FDA Premarket Approval for its WiSE CRT System, described by the source as the world’s first leadless left ventricular endocardial pacing device for CRT. BIOTRONIK and MicroPort have also introduced and expanded CRT-related product portfolios and technologies in different markets.
Future Outlook
The future of the cardiac resynchronization therapy market will be shaped by the growing heart failure population, wider guideline-based eligibility, remote monitoring, and technological advancements.
Significant opportunities exist in treating patients with challenging venous anatomy, prior infections, or unsuccessful CRT procedures. Leadless and alternative pacing strategies could expand the addressable patient population and offer more physiologic activation options for selected patients.
Emerging markets also offer considerable growth potential. Expanding implant capacity, strengthening specialist training programs, establishing referral networks, and improving reimbursement mechanisms could increase CRT adoption across Asia Pacific, Latin America, and the Middle East & Africa.
Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-resynchronization-therapy-market-113171
Conclusion
The global cardiac resynchronization therapy market is expected to experience steady growth through 2034, supported by the rising heart failure burden and broader use of guideline-based device therapy. The market is projected to increase from USD 7.26 billion in 2026 to USD 9.72 billion by 2034, registering a CAGR of 3.7%.
Technological advancements in connectivity, remote monitoring, physiologic pacing, and alternative implantation techniques will remain important to the industry’s development. At the same time, procedural complexity, infrastructure limitations, reimbursement differences, and variable patient response will continue to influence adoption.
Frequently Asked Questions
1. How big is the global cardiac resynchronization therapy market?
According to Fortune Business Insights, the global cardiac resynchronization therapy market was valued at USD 6.96 billion in 2025 and is projected to reach USD 9.72 billion by 2034.
2. At what CAGR is the cardiac resynchronization therapy market projected to grow?
The market is expected to grow at a CAGR of 3.7% from 2026 to 2034.
3. Which product segment leads the cardiac resynchronization therapy market?
The CRT-Defibrillator segment leads the market by product, supported by its use among eligible patients who also face an elevated risk of ventricular arrhythmias.
4. Which region dominated the cardiac resynchronization therapy market in 2025?
North America dominated the global market in 2025, accounting for 44.25% of the market share and generating approximately USD 3.08 billion in revenue.
5. What are the key factors driving the cardiac resynchronization therapy market?
The primary growth factors include the growing heart failure patient population and expanding guideline-based eligibility for CRT. Increasing use of remote monitoring, improved device connectivity, and technological advances are also supporting market development.
Curious About Japan’s Market? Explore the Latest Cardiac Resynchronization Therapy Market Insights